Replies to post #283510 on Anavex Life Sciences Corp (AVXL)

[JWC3]

Thanks for closing the loop TTTav66 and providing reference back to ANAVEX drugs further efficacy in therapies for a rare CNS disease!

[Steady_T]

Looks like he may not be using 2-73 in his research. Doesn't look like he has any results yet. If this research shows promise it could be a boost for one of the other Anavex drugs.

They’ll use a couple of certain molecules, or compounds, that target a specific protein that regulates how proteins fold inside a cell. The pharmaceutical company that developed these compounds, Anavex, has developed others, too, that are in clinical trials for other diseases.

“I’m hoping working with Anavex can prove to be beneficial for Batten disease patients,” Dr. Francis said. “Maybe we could also use this as kind of a model project that we can apply to other rare diseases as well.”

[tredenwater2]

Thanks for the reminder TTT. It truly makes one wonder how many Phd’s are studying our drug pre clinically in mouse models around the world, 10-15,20....? When Dr M mentionex a “backlog” in the Fda for Orphan Drug Designation a while back and we see a plethora of scientists around the world studying our drug in labs in mice it brings a supportive meaning to the “tip of the iceburg” comment. ODD is a string of inestimable pearls in terms of revenue!

Tred